CCND3 and osteosarcoma: In addition to CCND3 amplifications, amplifications of CCNE1 are common in osteosarcoma as well and the effect of CDK2 inhibition on tumor growth has been demonstrated by dinaciclib (SCH 727965) using patient‐derived xenografts [21].